Top Performing Mid-Cap Stocks of the Week
This surge followed NVIDIA Corporation's disclosure of a 1.74 million share stake in WeRide, as reported in a 13F filing.
President Trump's reported postponement of tariffs on packages under $800 from China and growing optimism surrounding China's DeepSeek AI model.
This jump came after the announcement of advanced acquisition discussions with Merck KGaA.
The company's launch of UltraRapid Whole Genome Sequencing, delivering results within 48 hours, fueled this increase.
This rise could be a rebound following last week's decline due to AI competition concerns related to China's DeepSeek AI model.
The company's better-than-expected fourth-quarter results led to this increase.
This rise followed the company's strong fourth-quarter financial results and subsequent price target increases by several analysts.
The company's settlement agreement with Teva Pharmaceutical, resolving patent litigation related to its Auvelity product, and subsequent price target increases by analysts contributed to this gain.
This increase likely resulted from the company's strong fourth-quarter earnings report and raised guidance for the year.
The company's positive data from a Phase 3 trial of its Roctavian treatment for hemophilia A likely drove this increase.